Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Alphamab Oncology ( (HK:9966) ) is now available.
Alphamab Oncology has scheduled a board meeting for March 25, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The meeting signals an upcoming disclosure of the company’s financial performance, which will be closely watched by investors and other stakeholders as an indicator of operational progress and corporate governance oversight.
The board currently consists of Chairman and executive director Dr. Xu Ting, executive director Ms. Liu Yang, non-executive director Mr. Cho Man, and independent non-executive directors Mr. Wu Dong, Ms. Wong Yan Ki Angel and Dr. Gao Xiang. This governance structure underscores a mix of executive leadership and independent oversight as the company prepares to report its latest annual results.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biotechnology company incorporated in the Cayman Islands and listed in Hong Kong, focusing on the research, development and commercialization of oncology therapies. The company operates through a board comprising executive, non-executive and independent non-executive directors overseeing its strategic and financial decisions.
Average Trading Volume: 1,444,908
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.43B
For detailed information about 9966 stock, go to TipRanks’ Stock Analysis page.